Special Considerations in the Management of HIV-Infected Patients From Minority Communities
Summary
- REALMRK trial was a single-arm study evaluating raltegravir in treatment-naive and -experienced patients, of whom 56% were black[Squires 2013b]
- Response rates were similar for black and nonblack patients
- Clinical adverse events considered drug related occurred in 14% of blacks and 9% of nonblacks
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content